Coherus BioSciences, Inc. (CHRS)

NASDAQ: CHRS · IEX Real-Time Price · USD
2.390
-0.030 (-1.24%)
At close: Mar 28, 2024, 4:00 PM
2.380
-0.010 (-0.42%)
After-hours: Mar 28, 2024, 7:54 PM EDT

Total Valuation

CHRS has a market cap or net worth of $275.01 million. The enterprise value is $635.96 million.

Market Cap 275.01M
Enterprise Value 635.96M

Important Dates

The last earnings date was Wednesday, March 13, 2024, after market close.

Earnings Date Mar 13, 2024
Ex-Dividend Date n/a

Share Statistics

CHRS has 111.36 million shares outstanding. The number of shares has increased by 21.30% in one year.

Shares Outstanding 111.36M
Shares Change (YoY) +21.30%
Shares Change (QoQ) +14.40%
Owned by Insiders (%) 1.35%
Owned by Institutions (%) 78.05%
Float 103.90M

Valuation Ratios

PE Ratio n/a
Forward PE 6.80
PS Ratio 1.07
Forward PS 0.88
PB Ratio n/a
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 2.47
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.43

Current Ratio 1.43
Quick Ratio 1.14
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -4.88

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -45.60%
Return on Capital (ROIC) -71.23%
Revenue Per Employee $840,667
Profits Per Employee -$777,425
Employee Count 306
Asset Turnover 0.49
Inventory Turnover 1.30

Taxes

Income Tax -380,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -62.77% in the last 52 weeks. The beta is 0.54, so CHRS's price volatility has been lower than the market average.

Beta (1Y) 0.54
52-Week Price Change -62.77%
50-Day Moving Average 2.39
200-Day Moving Average 3.33
Relative Strength Index (RSI) 51.01
Average Volume (30 Days) 4,561,259

Short Selling Information

The latest short interest is 25.91 million, so 23.27% of the outstanding shares have been sold short.

Short Interest 25.91M
Short Previous Month 24.20M
Short % of Shares Out 23.27%
Short % of Float 24.94%
Short Ratio (days to cover) 9.28

Income Statement

In the last 12 months, CHRS had revenue of $257.24 million and -$237.89 million in losses. Loss per share was -$2.53.

Revenue 257.24M
Gross Profit 98.25M
Operating Income -203.20M
Pretax Income -238.27M
Net Income -237.89M
EBITDA -191.46M
EBIT -197.73M
Loss Per Share -$2.53
Full Income Statement

Balance Sheet

The company has $117.75 million in cash and $478.70 million in debt, giving a net cash position of -$360.95 million or -$3.24 per share.

Cash & Cash Equivalents 117.75M
Total Debt 478.70M
Net Cash -360.95M
Net Cash Per Share -$3.24
Equity / Book Value -193.43M
Book Value Per Share -1.74
Working Capital 143.86M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$174.88 million and capital expenditures $559,000, giving a free cash flow of -$174.33 million.

Operating Cash Flow -174.88M
Capital Expenditures 559,000
Free Cash Flow -174.33M
FCF Per Share -$1.85
Full Cash Flow Statement

Margins

Gross margin is 38.19%, with operating and profit margins of -78.99% and -92.48%.

Gross Margin 38.19%
Operating Margin -78.99%
Pretax Margin -92.62%
Profit Margin -92.48%
EBITDA Margin -74.43%
EBIT Margin -76.86%
FCF Margin -67.77%

Dividends & Yields

CHRS does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -21.30%
Shareholder Yield -21.30%
Earnings Yield -86.50%
FCF Yield -63.39%

Analyst Forecast

The average price target for CHRS is $9.20, which is 284.94% higher than the current price. The consensus rating is "Strong Buy".

Price Target $9.20
Price Target Difference 284.94%
Analyst Consensus Strong Buy
Analyst Count 6
Revenue Growth Forecast (5Y) 26.71%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

CHRS has an Altman Z-Score of -3.67 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -3.67
Piotroski F-Score 2